91 related articles for article (PubMed ID: 20038828)
1. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of pivotal trials and FDA review of innovative devices.
Rising JP; Moscovitch B
PLoS One; 2015; 10(2):e0117235. PubMed ID: 25651420
[TBL] [Abstract][Full Text] [Related]
3. Safely Introducing New Surgical Devices in Minimally Invasive Gynecologic Surgery: An Argument for Use of the IDEAL Framework.
Ramanathan A; Davis-Cooper S; Iglesia CB
J Minim Invasive Gynecol; 2024 Jan; 31(1):21-27. PubMed ID: 37866715
[TBL] [Abstract][Full Text] [Related]
4. Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High-Risk Cardiovascular Devices, 2014-2022.
Swanson MJ; Uyeki CL; Yoder SR; Dhruva SS; Miller JE; Ross JS
Med Devices (Auckl); 2024; 17():165-172. PubMed ID: 38707869
[TBL] [Abstract][Full Text] [Related]
5. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.
Varma R; Richman EA; Ferris FL; Bressler NM
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6095-103. PubMed ID: 21123768
[No Abstract] [Full Text] [Related]
6. Characteristics and use of patient-reported outcomes of clinical trials for high-risk neurological medical devices that received FDA premarket approval from 2001 to 2022.
Ryan ME; Srivastava S; Wan L; Yang G; Zhang B
Contemp Clin Trials Commun; 2024 Feb; 37():101254. PubMed ID: 38269047
[TBL] [Abstract][Full Text] [Related]
7. Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet).
Zeitler EP; Al-Khatib SM; Drozda JP; Kessler LG; Kirtane AJ; Kong DF; Laschinger J; Marinac-Dabic D; Morice MC; Reed T; Sedrakyan A; Stein KM; Tcheng J; Krucoff MW;
Am Heart J; 2016 Jan; 171(1):64-72.e1-2. PubMed ID: 26699602
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of FDA's Review Concerns for Premarket Pathways and Predicate Product Selection of Device-led Combination Products].
Tian J
Zhongguo Yi Liao Qi Xie Za Zhi; 2023 Sep; 47(5):566-570. PubMed ID: 37753899
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Device Clinical Trials: Where Are the Women and What Are Their Outcomes?
Minhas A; Michos ED
J Womens Health (Larchmt); 2020 Oct; 29(10):1235-1236. PubMed ID: 32357082
[No Abstract] [Full Text] [Related]
10. Female Recruitment Into Cardiovascular Disease Trials.
Wu Y; Prasanna A; Miller HN; Ogungbe O; Peeler A; Juraschek SP; Turkson-Ocran RA; Plante TB
Am J Cardiol; 2023 Jul; 198():88-91. PubMed ID: 37210978
[No Abstract] [Full Text] [Related]
11. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.
Dhruva SS; Bero LA; Redberg RF
JAMA; 2009 Dec; 302(24):2679-85. PubMed ID: 20040556
[TBL] [Abstract][Full Text] [Related]
12. Postmarket surveillance of medical devices: current capabilities and future opportunities.
Blake K
J Interv Card Electrophysiol; 2013 Mar; 36(2):119-27. PubMed ID: 23479089
[TBL] [Abstract][Full Text] [Related]
13. FDA regulation of cardiovascular devices and opportunities for improvement.
Dhruva SS; Redberg RF
J Interv Card Electrophysiol; 2013 Mar; 36(2):99-105. PubMed ID: 23263896
[TBL] [Abstract][Full Text] [Related]
14. Defining the clinician's role in early health technology assessment during medical device innovation - a systematic review.
Smith V; Warty R; Nair A; Krishnan S; Sursas JA; da Silva Costa F; Vollenhoven B; Wallace EM
BMC Health Serv Res; 2019 Jul; 19(1):514. PubMed ID: 31337393
[TBL] [Abstract][Full Text] [Related]
15. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
16. Meta-Review of the Quantity and Quality of Evidence for Knee Arthroplasty Devices.
Gagliardi AR; Ducey A; Lehoux P; Ross S; Trbovich P; Easty A; Bell C; Takata J; Pabinger C; Urbach DR
PLoS One; 2016; 11(10):e0163032. PubMed ID: 27695077
[TBL] [Abstract][Full Text] [Related]
17. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study.
Hwang TJ; Sokolov E; Franklin JM; Kesselheim AS
BMJ; 2016 Jun; 353():i3323. PubMed ID: 27352914
[TBL] [Abstract][Full Text] [Related]
18. Time Series Analysis of the Effectiveness and Safety of Capsule Endoscopy between the Premarketing and Postmarketing Settings: A Meta-Analysis.
Iijima K; Umezu M; Iwasaki K
PLoS One; 2016; 11(6):e0153662. PubMed ID: 27248140
[TBL] [Abstract][Full Text] [Related]
19. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
20. Regulatory science: Trust and transparency in clinical trials of medical devices.
Kramer DB; Cutlip DE
Nat Rev Cardiol; 2015 Sep; 12(9):503-4. PubMed ID: 26194550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
